Bethesda, MD (Aug. 14, 2014) Fecal microbiota transplantation (FMT) is one of the most innovative new treatments of the 21st century. Experts believe that this procedure, which transplants microbes from one human gut to another through fecal matter, could offer the cure to a vast range of diseases and shed new light on the role of the microbiome in gastrointestinal diseases. New research presented this weekend at the American Gastroenterological Association's 2014 James W. Freston Conference in Chicago, IL, highlights significant advances in this field, and confirms the promise of FMT to advance our understanding of GI disease and aid in the development of new microbiome-based therapeutics to treat a broad range of GI disorders.
"The 2014 AGA James W. Freston Conference promises to be an important and stimulating meeting in microbiome and FMT research and technology," said course directors Stacy A. Kahn, MD, and David T. Rubin, MD, AGAF, both from The University of Chicago Medicine. "This is the first international conference on FMT and brings together leaders from across the field and will highlight advances in basic science and clinical research. In addition, the conference will also create a forum to discuss the ethical and regulatory issues in this emerging field."
FMT Beyond C. Difficile
While FMT has been proven to be safe and effective for patients with recurrent C. difficile infection, its efficacy in treating other diseases is still in question. Data presented at the AGA James W. Freston Conference will provide evidence that FMT is an effective treatment for a range of other GI disorders. One study reports that 70 percent of subjects who received FMT for refractory irritable bowel syndrome (IBS) had a resolution and/or improved symptoms. Patients reported improved abdominal pain (72 percent), bowel habit (69 percent), dyspepsia (67 percent), bloating (50 percent) and flatus (42 percent). Quality of life was also improved in 46 percent of patients.
Data also confirm the potential for FMT in treating inflammatory bowel disease (IBD), both ulcerative colitis and Crohn's disease. A study out of Montefiore Medical Center finds that colonoscopic FMT, followed by self-administered fecal enemas, resulted in improved symptoms and decreased medication requirements, especially in IBD patients with concomitant C. difficile infection.
On the Horizon: Orally Delivered Microbes
FMT has multiple liabilities, including invasive delivery, cost and complexity of donor management, variability of FMT preparation, and the potential to transmit pathogens. A new study, to be presented at the meeting, holds the answer to these challenges an orally delivered community of microbes. SER---109, developed by Seres Health, Inc., proved to be remarkably efficacious and safe with a 100 percent cure rate for the treatment of recurrent C. difficile infection in the study population. The pill works to rapidly repair the microbial imbalance cause by chronic antibiotic treatment for C. difficile by inducing the formation of a diverse and healthy microbiome. This pill has the potential to replace FMT and maximize utility for clinicians and patients.
New Understanding of the FMT Patient
Due to the "yuck" factor, some patients and clinicians are reluctant to consider FMT. New data to be presented at the AGA James W. Freston Conference sheds light on the factors that lead to acceptance of FMT. The study found that patients who have children are more likely to accept FMT, suggesting that parents may be more willing to try emerging procedures for the sake of their children. Having a college degree was also a significant factor, implying that a better understanding of the disease may affect one's willingness to undergo FMT. The main concern for undergoing FMT was the risk of disease transmission. Since FMT is a potentially life-saving procedure, medical practitioners should use this knowledge when counseling patients and their families on the decision to undergo FMT.
|Contact: Rachel Steigerwald|
American Gastroenterological Association